These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 24615378)

  • 21. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.
    Choi WM; Yip TC; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Clark LJ; Jafry Z; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Wong GL; Lim YS
    Hepatology; 2024 Aug; 80(2):428-439. PubMed ID: 38436992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G; Viganò M; Loglio A; Lampertico P
    Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
    Singal AK; Salameh H; Kuo YF; Fontana RJ
    Aliment Pharmacol Ther; 2013 Jul; 38(2):98-106. PubMed ID: 23713520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
    Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
    Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee EJ; Shin HJ; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):832-837. PubMed ID: 31988073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients.
    Yasunaka T; Ikeda F; Wada N; Morimoto Y; Fujioka S; Toshimori J; Kobashi H; Kariyama K; Morimoto Y; Takayama H; Seno T; Takaguchi K; Moriya A; Miyatake H; Okamoto R; Yabushita K; Takaki A; Yamamoto K
    Acta Med Okayama; 2016; 70(1):1-12. PubMed ID: 26899604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
    Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
    Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
    Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.
    Qu J; Yu Z; Li Q; Chen Y; Xiang D; Tan L; Lei C; Bai W; Li H; Shang Q; Chen L; Hu X; Lu W; Li Z; Chen D; Wang X; Zhang C; Xiao G; Qi X; Chen J; Zhou L; Chen G; Li Y; Zeng Z; Rong G; Dong Z; Chen Y; Lou M; Wang C; Lu Y; Zhang C; Yang Y
    Trials; 2014 Nov; 15():438. PubMed ID: 25381721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
    J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR; Lee HJ; Kim TN; Lee KS
    J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment.
    Kim NH; Cho YK; Kim BI; Kim HJ
    Dig Dis Sci; 2018 Oct; 63(10):2792-2799. PubMed ID: 29948568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
    Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
    World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B.
    Jun CH; Hong HJ; Chung MW; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS
    World J Gastroenterol; 2013 Oct; 19(40):6834-41. PubMed ID: 24187458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
    Hiramatsu N; Yamada R; Takehara T
    J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS
    Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.